Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

NCT06143878

Active Not RecruitingPhase 3

Sponsor: Janssen Research & Development, LLC

Conditions: Plaque Psoriasis

Interventions: JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo

Countries: United States, Argentina, Australia, Brazil, Canada, Germany, Hungary, Japan

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 26 weeks prior to the first administration of study intervention
* Total body surface area (BSA) greater than or equal to (\>=)10 percent (%) at screening and baseline
* Total psoriasis area and severity index (PASI) \>=12 at screening and baseline
* Total investigator global assessment (IGA) \>=3 at screening and baseline
* Candidate for phototherapy or systemic treatment for plaque psoriasis

Exclusion Criteria:

* Nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
* Current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
* A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
* Known allergies, hypersensitivity, or intolerance to JNJ-77242113, deucravacitinib, or to any of the excipients or components of the study intervention
* Major surgical procedure, (for example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
Locations (164)
  • Phoenix, Arizona, United States
  • Scottsdale, Arizona, United States
  • Fort Smith, Arkansas, United States
  • Fountain Valley, California, United States
  • Fremont, California, United States
  • Sacramento, California, United States
  • Santa Ana, California, United States
  • Santa Monica, California, United States
  • Miami, Florida, United States
  • North Miami Beach, Florida, United States
  • Ocala, Florida, United States
  • Tampa, Florida, United States
  • Alpharetta, Georgia, United States
  • Macon, Georgia, United States
  • Chicago, Illinois, United States
  • Rolling Meadows, Illinois, United States
  • Skokie, Illinois, United States
  • West Dundee, Illinois, United States
  • Indianapolis, Indiana, United States
  • Plainfield, Indiana, United States
  • Louisville, Kentucky, United States
  • Lake Charles, Louisiana, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Clarkston, Michigan, United States
  • Detroit, Michigan, United States
  • Fort Gratiot, Michigan, United States
  • Saint Joseph, Missouri, United States
  • Omaha, Nebraska, United States
  • Las Vegas, Nevada, United States
  • + 134 more on CT.gov